Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1008-1017, 2008. First published April 10, 2008; 10.1373/clinchem.2007.097352
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.097352v1
clinchem.2007.097352v2
54/6/1008    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Siegel, R. W.
Right arrow Articles by Tyner, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siegel, R. W.
Right arrow Articles by Tyner, J.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2008;54:1008-1017.)
© 2008 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Affinity Maturation of Tacrolimus Antibody for Improved Immunoassay Performance

Robert W. Siegel1,a, Wade Baugher1, Tanya Rahn1, Susan Drengler1 and Joan Tyner1

1 Core R&D, Diagnostic Division, Abbott Laboratories, Abbott Park, IL.

aAddress correspondence to this author at: Eli Lilly and Company, Lilly Research Laboratories, P.O. Box 708, Greenfield, IN 46140. Fax (317) 433-6963; e-mail siegelro{at}lilly.com.

Background: Organic solvents used for extraction of tacrolimus from whole blood samples lower the apparent affinity of the antibody used in a diagnostic immunoassay, thereby affecting the detection limit.

Methods: We used in vitro recombinant antibody engineering to screen and isolate clones from diverse libraries with mutagenic complementarity regions (CDRs) from tacrolimus 1-60-46 hybridoma cell line, with improved binding to tacrolimus in the presence of 10% methanol organic solvent solution.

Results: We isolated a number of clones with mutations in variable heavy (VH) CDR 2, variable light (VL) CDR 1, and VL CDR 3 with improved binding. Various combinatorial pairings constructed from these individual mutations contained >10-fold improvements in both the dissociation rate and overall equilibrium affinity constants. Selected clones produced as IgG have increased functional sensitivity, with a 3- to 6-fold reduction in the limit of detection relative to the parental tacrolimus 1-60-46 monoclonal antibody in the Architect® Tacrolimus immunodiagnostic assay.

Conclusions: The recent advent of recombinant in vitro antibody display technologies in general, and yeast surface display in particular, allows the flexibility to engineer new or augment specific analytical characteristics, such as affinity, specificity, or stability, into previously isolated and otherwise desirable antibodies to enhance assay performance. These in vitro selections can also be performed under conditions meant to mimic the assay in which the reagent will ultimately be used, to increase the likelihood of successful assay development.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.